Muscarella Lucia Anna, Turchetti Daniela, Fontana Andrea, Baorda Filomena, Palumbo Orazio, la Torre Annamaria, de Martino Danilo, Franco Renato, Losito Nunzia Simona, Repaci Andrea, Pagotto Uberto, Cinque Luigia, Copetti Massimiliano, Chiofalo Maria Grazia, Pezzullo Luciano, Graziano Paolo, Scillitani Alfredo, Guarnieri Vito
Laboratory of Oncology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo 71013, Italy.
Medical Genetics, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna 40138, Italy.
Oncotarget. 2018 Apr 17;9(29):20721-20733. doi: 10.18632/oncotarget.25067.
The Hyperparathyroidism with Jaw-Tumours syndrome is caused by mutations of the gene: it has been suggested that early onset of the disease and high Ca levels may predict the presence of a mutation. We searched for large deletions at the locus in patients with: HPT-JT (nr 2), atypical adenoma (nr 7) or sporadic parathyroid carcinoma (nr 11) with a specific MLPA and qRT-PCR assays applied on DNA extracted from whole blood. A Medline search in database for all the papers reporting a gene mutation, clinical/histological diagnosis, age at onset, Ca, PTH levels for familial/sporadic cases was conducted with the aim to possibly identify biochemical/clinical markers predictive, in first diagnosis, of the presence of a gene mutation. A novel genomic deletion of the first 10 exons of the gene was found in a 3-generation HPT-JT family, confirmed by SNP array analysis. A classification tree built on the published data, showed the highest probability of having a mutation in subjects with age at the onset < 41.5 years (44/47 subjects, 93.6%, had the mutation). Whereas the lowest probability was found in subjects with age at the onset ≥ 41.5 years and Ca levels <13.96 mg/dL (7/20 subjects, 35.0%, had the mutation, odds ratio = 27.1, < 0.001). We report a novel large genomic CDC73 gene deletion identified in an Italian HPT-JT family. Age at onset < 41.5 ys and Ca > 13.96 mg/dL are predictive for the presence of a CDC73 genetic lesion.
有人提出,疾病的早发和高钙水平可能预示着该突变的存在。我们运用特定的多重连接依赖探针扩增(MLPA)和定量逆转录聚合酶链反应(qRT-PCR)检测方法,对从全血中提取的DNA进行检测,以寻找患有颌骨肿瘤综合征性甲状旁腺功能亢进(2例)、非典型腺瘤(7例)或散发性甲状旁腺癌(11例)患者的该基因座大片段缺失情况。在数据库中进行医学文献检索,查找所有报告该基因突变、临床/组织学诊断、发病年龄、钙和甲状旁腺激素水平的家族性/散发性病例的论文,目的是可能识别在初次诊断时预测该基因突变存在的生化/临床标志物。在一个三代颌骨肿瘤综合征性甲状旁腺功能亢进家族中发现了该基因前10个外显子的一个新的基因组缺失,经单核苷酸多态性(SNP)阵列分析证实。基于已发表数据构建的分类树显示,发病年龄<41.5岁的受试者发生该突变的概率最高(47例受试者中有44例,93.6%,发生了突变)。而发病年龄≥41.5岁且钙水平<13.96mg/dL的受试者发生该突变的概率最低(20例受试者中有7例,35.0%,发生了突变,优势比=27.1,P<0.001)。我们报告了在一个意大利颌骨肿瘤综合征性甲状旁腺功能亢进家族中鉴定出的一个新的该基因大片段基因组缺失。发病年龄<41.5岁和钙>13.96mg/dL可预测该基因病变的存在。